If You Invested $3,000 in CRISPR Therapeutics in 2018, This Is How Much You Would Have Today
CRISPR Therapeutics (NASDAQ: CRSP) is one of the most exciting biotechs on the market today, because it's pushing the limits of what is possible when it comes to treating hereditary diseases. It's all made possible by the company's gene-editing technology, which (as the name implies) is based on the much-hyped CRISPR-Cas9 system.
But does sophisticated tech make for a good investment, even when the business has no products for sale? To answer this question, let's take a look at how well this stock performed for shareholders over the last few years and get a feeling for whether it might be a good pick today.
Image source: Getty Images
Source Fool.com
